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Purpose: To analyze overall survival (OS), prostate cancer (PCa)-specific survival 
(PCaSS), and non-PCaSS according to the Charlson Comorbidity Index (CCI) after 
radical prostatectomy (RP) for PCa. Materials and Methods: Data from 336 patients 
who had RP for PCa between 1992 and 2005 were analyzed. Data included age, pre-
operative prostate-specific antigen (PSA), prostate volume, clinical stage, and patho-
logic stage. Pre-existing comorbidities were evaluated by the CCI, and patients were 
classified into two CCI score categories (0, ≥1). Results: The mean age of patients 
was 64.31±6.12 years. The median PSA value (interquartile range, IQR) was 11.30 
(7.35 and 21.02) ng/mL with a median follow-up period (IQR) of 96.0 (85.0 and 121.0) 
months. The mean CCI was 0.28 (0-4). Five-year OS, PCaSS, and non-PCaSS were 
91.7%, 96.3%, and 95.2%, respectively. Ten-year OS, PCaSS, and non-PCaSS were 
81.9%, 92.1%, and 88.9%, respectively. The CCI had a significant influence on OS 
(p=0.022) and non-PCaSS (p=0.008), but not on PCaSS (p=0.681), by log-rank test. 
In multivariate Cox regression analysis, OS was independently associated with the 
CCI [hazard ratio (HR)=1.907, p=0.025] and Gleason score (HR=2.656, p<0.001). 
PCaSS was independently associated with pathologic N stage (HR=2.857, p=0.031), 
pathologic T stage (HR=3.775, p=0.041), and Gleason score (HR=4.308, p=0.001). 
Non-PCaSS had a significant association only with the CCI (HR=2.540, p=0.009). 
Conclusion: The CCI was independently associated with both OS and non-PCaSS 
after RP, but the CCI had no impact on PCaSS. The comorbidities of a patient should 
be considered before selecting RP as a curative modality for PCa.
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INTRODUCTION
Prostate cancer (PCa) is the most common nondermatologic cancer in Western 
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son scores, and clinical and final pathologic stages. Data re-
garding mortality and cause of death were also obtained from 
patient medical records in the database of the Yonsei Cancer 
Registry Center at the Severance Hospital. Tumors were 
staged according to the 2002 American Joint Committee on 
Cancer staging guidelines. The follow-up period was calcu-
lated from the time of surgery to the date of the last known 
contact with the patient or the date of death. The primary out-
come for this study was death from causes other than PCa.
Good clinical practice protocols
The study was performed in agreement with applicable laws 
and regulations, good clinical practices, and ethical principles 
as described in the Declaration of Helsinki. The Institutional 
Review Board of the hospital approved this study protocol 
(approval number: 4-2012-0906). This report was prepared 
in compliance with the Strengthening the Reporting of Ob-
servational Studies in Epidemiology checklist (version 3, ac-
cessible at http://www.strobe-statement.org).19
Definition of survival
PCa-specific survival (PCaSS) was defined as the time from 
RP to death due to PCa or complications of this disease. Over-
all survival (OS) was defined as the time from RP to death by 
any cause. Non-PCaSS was defined as the time from RP to 
death due to causes other than PCa or complications of PCa. 
If PCa was recorded as the underlying cause of death, or if a 
patient with known metastatic PCa died, then mortality was 
considered to be a result of PCa. Deaths in which PCa was 
not the underlying cause were classified as non-PCaSS or due 
to causes other than PCa.
Charlson Comorbidity Index
The CCI score was calculated from hospital discharge re-
cords and assigned according to the Dartmouth-Manitoba 
modification of the CCI, which was used to convert Interna-
tional Classification of Disease 10 code (ICD-10), and is 
more applicable to studies of surgical patients.20 The CCI 
features 19 conditions that have assigned scores of 1, 2, 3, 
or 6 based upon severity of disease. The CCI score was de-
rived by adding the scores for all comorbidities. Based on 
the distribution of CCI score in our patient cohort, the men 
who received RP were classified into two CCI score catego-
ries, which were 0 or ≥1. PCa was not scored in the CCI cal-
culation for this study. Two researchers (JYL and DHL) in-
dependently assessed medical records and assigned CCI 
scores to all patients. Discrepancies in scoring between the 
men.1 More than 90% of diagnoses involve localized tumors 
that are potentially curable by radical prostatectomy (RP).2 
The incidence of PCa is higher in Western countries. A West-
ern lifestyle, characterized by high caloric intake, low physi-
cal activity, and obesity, is believed to increase risk for PCa.3 
The incidence of PCa in Asian men has also been increasing, 
especially in Japan, China, and Korea.4,5 PCa ranked as the 
fifth leading male neoplasm among Japanese men,6 and the 
sixth highest cause of cancer-related mortality in 2009.7 Mor-
bidity due to PCa was reported to be 5.1% in Korean men 
≥65 years old in 1990 and 9.1% in 2005, indicating an ap-
proximately two-fold increase.8 In 2011, PCa was reported to 
be the fifth most common malignancy in Korean men.9
RP for PCa carries an inherent risk of post-treatment mor-
bidity. Treatment for PCa can change sexual, urinary, and 
bowel habits, which adversely affect post-treatment quality of 
life.10 The decision to perform RP for PCa should optimally 
weigh the benefit of treatment against the risks of treatment-
related morbidity. Ideally, RP should be offered to men with a 
life expectancy of at least 10 years.11,12 However, life expec-
tancy is a subjective measurement with significant bias.13 
The presence of comorbidities is one of the important 
predictors of survival from malignancies.14 Several studies 
have attempted to develop comorbidity assessment tools 
for counseling patients about life expectancy before under-
going RP. These assessment tools include life tables, co-
morbidity indices, and nomograms. Although there is no 
consensus on which comorbidity assessment tool is most 
useful, the Charlson Comorbidity Index (CCI) has been one 
of the most extensively studied in men with PCa.15-18 Thus, 
the aim of this study was to evaluate the association be-
tween the CCI score and death from causes other than PCa 
among Korean men with clinically localized PCa who un-
derwent RP. To our best knowledge, this is the first study to 
examine the relationship between the CCI and long-term 
survival outcomes of the patients with prostate cancer in 
Asia as well as in Korea.
MATERIALS AND METHODS
　　　
Patient cohort
Data from 336 patients who underwent RP for PCa be-
tween 1992 and 2005 at the Severance Hospital in Seoul, 
Korea were analyzed. Data included age, height and weight 
at the time of surgery, date of surgery, preoperative serum 
prostate-specific antigen (PSA), biopsy and pathologic Glea-
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The median PSA (interquartile range, IQR) was 11.30 (7.35 
and 21.02) ng/mL with a median follow-up period (IQR) of 
96 (85 and 121) months. The mean CCI at the time of RP 
was 0.28 (range 0-4) in 336 men. 
A CCI score of 0 was assigned to 266 (79.2%) patients. A 
CCI score of 1 was assigned to 51 (15.2%) patients. A CCI 
score of 2 was assigned to 16 (4.8%) patients. CCI scores of 
3 or 4 were assigned to three (0.9%) patients. Subjects were 
then divided into two subgroups according to CCI=0 (Group 
1, n=266) or ≥1 (Group 2, n=70). Median PSA (IQR), which 
were 12.00 (7.75, 21.95) ng/mL in Group 1 and 9.56 (6.12, 
15.02) ng/mL, demonstrated statistical differences in both 
groups (p=0.007). Median follow-up periods (IQR) were 99 
(86, 109) months in Group 1 and 91 (82.75, 111.20) months 
in Group 2 (p=0.001). Only 19 men (27.1%) in Group 2 had 
histories of other malignancies, including stomach cancer 
(eight cases), renal cell carcinoma (six cases), colorectal 
cancer (two cases), laryngeal cancer (one case), duodenal 
cancer (one case), and bladder cancer (one case). In con-
trast, patients in Group 1 did not have histories of other ma-
lignancies (p<0.001). There were no significant differences 
in mean age, biopsy Gleason score, BMI, D’Amico risk 
stratification, or pathologic stage between the two groups 
(Table 1).
Five-year OS, PCaSS, and non-PCaSS were 91.7% (95% 
two researchers were resolved by discussion until a consen-
sus was reached or by independent assessment by a third 
researcher (KSC).
Statistical analyses
Kaplan-Meier curves were used to estimate the probabili-
ties of death from non-PCa-related causes and PCa-related 
causes by two CCI categories. The Cox proportional-haz-
ards regression model was also used to estimate the hazard 
ratio (HR) and 95% confidence interval (CI) of death from 
non-PCa-related causes and PCa-related causes, age, body 
mass index (BMI), preoperative PSA, pathologic stage, and 
pathologic Gleason score. Integrated area under the curve 
(iAUC) was based on Cox proportional-hazards regression 
model.21 Two-sided tests were performed and p-values 
<0.05 were considered statistically significant. Statistical 
analyses were carried out with R (R version 3.0.1, R Foun-
dation for Statistical Computing, Vienna, Austria; http://
www.r-project.org) and its risksetROC package for iAUC 
based on Cox proportional-hazards regression model.
RESULTS
 
The mean age of enrolled patients was 64.31±6.12 years. 
Table 1. Clinical and Pathologic Features of 336 Korean Men Treated with RP Stratified by the CCI
CCI=0 CCI≥1 p value
No. of patients 266 70
Mean age 64.01±6.28 65.43±5.39 0.085*
Median follow-up (months, IQR) 99 (86, 109)        91 (82.75, 111.20) 0.001†
Biopsy Gleason score   6.83±1.36   6.77±1.36 0.187*
Median PSA (ng/mL, IQR)   12.00 (7.75, 21.95) 9.56 (6.12, 15.02) 0.007†
BMI (kg/m2) 23.94±2.61 23.89±2.76 0.893*
D’Amico risk stratification (%) 0.183‡
    Low   37 (13.9) 16 (22.9) 0.100‡
    Intermediate   76 (28.6) 17 (24.3) 0.574‡
    High 153 (57.5) 37 (52.9) 0.572‡
Pathologic stage (%) 0.090‡
    pT2 124 (46.6) 38 (54.3) 0.313‡
    pT3 119 (44.7) 22 (31.4) 0.061‡
    pT4   23 (8.6) 10 (14.3) 0.236‡
Other malignancy (%)     0 (0) 19 (27.1)|| <0.001§
RP, radical prostatectomy; CCI, Charlson Comorbidity Index; IQR, interquartile range; PSA, prostate-specific antigen; BMI, body mass index.
*Student’s or Welch’s 2-sample t-test.
†Wilcoxon rank sum test (if p-value was less than 0.05 in Shapiro-Wilk normality test).
‡Chi-square test.
§Fisher’s exact test.
||Other malignancies included stomach cancer (eight cases), renal cell carcinoma (six cases), colorectal cancer (two cases), laryngeal cancer (one case), 
duodenal cancer (one case), and bladder cancer (one case).
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did not affect PCaSS (p=0.681) (Fig. 1B, C and D). In multi-
variate Cox regression analyses, OS was independently as-
sociated with CCI (HR=1.907, p=0.025) and Gleason score 
(HR=2.656, p<0.001). PCaSS was associated with patholog-
ic N stage (HR=2.857, p=0.031), pathologic T stage (HR= 
3.775, p=0.041), and Gleason score (HR=4.308, p=0.001). 
CI 0.888-0.947), 96.3% (95% CI 0.943-0.984), and 95.2% 
(95% CI 0.929-0.988), respectively. Ten-year OS, PCaSS, 
and non-PCaSS were 81.9% (95% CI 0.772-0.868), 92.1% 
(95% CI 0.887-0.956), and 88.9% (95% CI 0.849-0.930), re-
spectively (Fig. 1A). CCI had a significant influence on OS 
(p=0.022) and non-PCaSS (p=0.008) by log-rank test, but 
Fig. 1. (A) Kaplan-Meier curves for OS, PCaSS, and (C) non-PCaSS for 336 Korean men who received radical prostatectomy. Kaplan-Meier 
curves and log-rank tests for (B) OS, (C) PCaSS, and (D) non-PCaSS of 336 Korean men who received radical prostatectomy according to 
the Charlson Comorbidity Index. (E) The iAUC which was based on Cox proportional-hazards regression model survival demonstrated that 
the AUC of non-PCaSS was higher than OS and PCaSS. OS, overall survival; PCaSS, prostate cancer-specific survival; non-PCaSS, non-
prostate cancer-specific survival; iAUC, integrated area under the curve; CCI, Charlson Comorbidity Index; HR, hazard ratio.
Time in months
Time in months
Time in months
Time in months
Time in months
0.0
0.0
0.40
0.0
0.0
0.2
0.2
0.45
0.2
0.2
0.4
0.4
0.50
0.4
0.4
0.6
0.6
0.55
0.6
0.6
0.8
0.8
0.65
0.60
0.8
0.8
1.0
1.0
0.70
1.0
1.0
Su
rv
iva
l
Pr
os
ta
te
 c
an
ce
r-s
pe
ci
fic
 su
rv
iva
l
AU
C
Ov
er
al
l s
ur
viv
al
N
on
-p
ro
st
at
e 
ca
nc
er
-s
pe
ci
fic
 su
rv
iva
l
0
0
0
0
0
336
266
70
266
70
266
70
0
≥1
0
≥1
Number at risk
CCI number at risk
CCI number at risk
CCI number at risk
50
50
50
50
50
315
254
61
254
61
254
61
100
100
100
100
153
131
22
131
22
131
22
150
150
100
150
150
48
44
4
44
4
44
4
200
200
150
200
200
7
7
0
7
0
7
0
250
250
200
250
250
0
0
0
0
0
0
0
   OS   
   PCaSS 
   Non-PCaSS  
CCI
   0   
   ≥1 
   OS   
   PCaSS 
   Non-PCaSS  
CCI
   0   
   ≥1 
CCI
   0   
   ≥1 
A
C
E
B
D
HR=1.92 (1.09-3.38)
Log-rank p=0.022
HR=2.51 (1.24-5.07)
Log-rank p=0.008
HR=1.23 (0.46-3.30)
Log-rank p=0.681
0
≥1
Joo Yong Lee, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 2   March 2014320
group (Table 3).
DISCUSSION
The National Comprehensive Cancer Network guidelines 
for PCa suggest that RP and/or radiation therapy should be 
offered only to men who are likely to survive for more than 
10 years.22 According to these guidelines, urologists have to 
make treatment decisions based upon the life expectancy of 
Non-PCaSS had a significant association only with CCI 
(HR=2.540, p=0.009) (Table 2). The iAUC, based on Cox 
regression model according to CCI, also demonstrated that 
the AUC of non-PCaSS was higher than OS and PCaSS 
(Fig. 1E).
Patients were then sub-grouped as pT2 (n=162) and pT3/4 
(n=174). Patients in the pT2 group had disease confined to 
the prostate. The CCI correlated with OS and non-PCaSS, 
but not PCaSS. However, the CCI was not associated with 
OS, PCaSS, or non-PCaSS in the non-organ confined pT3/4 
Table 2. Univariate and Multivariate Cox Proportional-Hazards Regression Model of OS, PCaSS, Non-PCaSS
Survival Covariates
Univariate Multivariate*
HR 95% CI p value HR 95% CI p value
OS
Age 1.047 1.004-1.093 0.034
PSA 0.998 0.991-1.005 0.571
BMI 0.995 0.910-1.087 0.904
Node positive 1.870 0.849-4.118 0.120
Margin 1.186 0.717-1.960 0.506
Gleason score 1.351 1.089-1.676 0.006
    ≤6 Reference - -
    7 1.110 0.564-2.186 0.763
    ≥8 2.834 1.474-5.447 0.002 2.656 1.596-4.422 <0.001
Stage ≥pT3 (vs. <pT2) 1.793 1.063-3.024 0.029
CCI ≥1 (vs. 0) 1.919 1.089-3.380 0.024 1.907 1.083-3.359 0.025
PCaSS
Age 1.080 1.080-1.158 0.030
PSA 0.999 0.994-1.005 0.849
BMI 0.979 0.853-1.123 0.762
Node positive 4.528   1.801-11.384 0.001 2.857 1.102-7.407 0.031
Margin 2.407 1.038-5.580 0.041
Gleason score 2.122 1.487-3.029 <0.001
    ≤6 Reference - -
    7 5.858   0.732-46.887 0.096
    ≥8 24.088     3.187-182.050 0.002 4.308 1.837-10.100 0.001
Stage ≥pT3 (vs. <pT2) 7.361   2.202-24.600 0.001 3.775 1.056-13.494 0.041
CCI ≥1 (vs. 0) 1.229 0.458-3.297 1.229
Non-PCaSS
Age 1.027 0.974-1.083 0.330
PSA 0.994 0.980-1.009 0.422
BMI 1.006 0.895-1.130 0.923
Node positive 0.414 0.057-3.025 0.385
Margin 0.736 0.376-1.441 0.371
Gleason score 1.014 0.774-1.328 0.921
    ≤6 Reference - -
    7 0.744 0.344-1.608 0.529
    ≥8 1.179 0.514-2.702 0.384
Stage ≥pT3 (vs. <pT2) 1.099 0.573-2.108 0.777
CCI ≥1 (vs. 0) 2.508 1.240-5.073 0.011 2.540 1.256-5.138 0.009
OS, overall survival; PCaSS, prostate cancer-specific survival; Non-PCaSS, non-prostate cancer-specific survival; PSA, prostate-specific antigen; BMI, body 
mass index; CCI, Charlson Comorbidity Index; HR, hazard ratio; CI, confidence interval.
*Multivariate Cox proportional-hazards regression model with forward stepwise selection was performed.
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surgical treatment. Lund, et al.24 also demonstrated a corre-
lation between comorbidity and survival in Danish patients 
with PCa, suggesting that comorbidities were negative prog-
nostic factors for survival in men with PCa. Recently, the 
European Multicenter Prostate Cancer Clinical and Transla-
tional Research Group reported that long-term PCaSS after 
RP was modest and represented the leading cause of death in 
young and healthy patients. However, according to a multi-
institutional study involving a cohort of 3832 men who re-
ceived RP, patients with PCa who were older, sicker, and 
had multiple risk factors were at the highest risk of dying 
from non-PCa-related causes.25
Daskivich, et al.26 also assessed the competing risks for 
non-PCa-related mortality and PCa-related mortality among 
1482 men in the California Cancer Registry who had non-
metastatic prostate cancer and differing CCI scores and tu-
mor risks. After a mean follow-up period of 6.0 years, 370 
(25%) men died from other causes, whereas 44 (3%) died 
of PCa. According to a competing risks regression analysis, 
each point of increase in the CCI was associated with a 
2-fold increase in hazard of non-PCa-related mortality. Fur-
thermore, they concluded that men with the highest CCI 
a patient and the characteristics of the tumor. However, age 
is not the sole determinant of a patient’s life expectancy. Co-
morbidities should also be considered. To our best knowl-
edge, the current study is the first to examine the relationship 
between the CCI and mortality in Asian men with PCa. The 
results showed that the CCI was independently associated 
with both OS and non-PCaSS in patients with localized tu-
mors who were treated with RP. However, the CCI had no 
impact on PCaSS in these patients. This indirectly suggests 
that comorbidities should be considered during selection of 
treatment modalities for PCa. Furthermore, the data suggest 
that radical surgeries should be reserved for physically 
healthy patients. 
Population-based or retrospective cohort studies have been 
performed in Western countries to evaluate relationships 
between cancer-specific survival and preoperative comor-
bidities. Post, et al.23 showed that comorbidity was the most 
important prognostic factor for 3-year survival among 1337 
men who were younger than 75 years old and were diag-
nosed with T1-T3M0 PCa. Furthermore, subgroup analysis 
revealed that individuals treated with RP were younger and 
had fewer comorbid conditions than patients receiving non-
Table 3. Univariate Cox Proportional-Hazards Regression Model of OS, PCaSS, Non-PCaSS According to pT2 and pT3/4
Survival Covariates
Organ-confined (n=162) Non-organ-confined (n=174)
HR 95% CI p value HR 95% CI p value
OS
Age 1.035 0.974-1.100 0.270 1.053 0.992-1.118 0.090
PSA 0.997 0.970-1.025 0.825 0.996 0.987-1.006 0.423
BMI 1.035 0.882-1.214 0.676 0.968 0.871-1.076 0.550
Node positive - - - 1.480 0.652-3.361 0.349
Margin 0.993 0.388-2.540 0.988 0.889 0.461-1.715 0.727
Gleason score 0.992 0.673-1.464 0.969 1.456 1.098-1.931 0.009
CCI ≥1 (vs. 0) 3.014 1.226-7.413 0.016 1.568 0.742-3.313 0.238
PCaSS
Age 0.985 0.842-1.153 0.854 1.108 1.016-1.209 0.021
PSA 1.011 0.982-1.040 0.478 0.996 0.984-1.009 0.566
BMI 1.111 0.714-1.729 0.639 0.960 0.834-1.106 0.572
Node positive - - - 2.569 1.001-6.592 0.047
Margin 1.246   0.112-13.848 0.858 1.360 0.530-3.488 0.522
Gleason score 1.268 0.427-3.765 0.669 1.827 1.231-2.711 0.003
CCI ≥1 (vs. 0) - - - 1.591 0.584-4.336 0.364
Non-PCaSS
Age 1.043 0.976-1.114 0.211 0.997 0.920-1.081 0.945
PSA 0.988 0.948-1.029 0.558 0.996 0.981-1.011 0.574
BMI 1.023 0.862-1.214 0.796 0.979 0.834-1.148 0.792
Node positive - - - 0.417 0.055-3.148 0.396
Margin 0.955 0.343-2.653 0.929 0.545 0.210-1.415 0.212
Gleason score 0.956 0.631-1.449 0.833 1.110 0.738-1.670 0.615
CCI ≥1 (vs. 0) 3.831 1.481-9.909 0.006 1.540 0.501-4.736 0.451
OS, overall survival; PCaSS, prostate cancer-specific survival; Non-PCaSS, non-prostate cancer-specific survival; PSA, prostate-specific antigen; BMI, body 
mass index; CCI, Charlson Comorbidity Index; HR, hazard ratio; CI, confidence interval.
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postoperative treatments, which may be an important con-
founding factor in our study. Despite these limitations, the 
present study demonstrates a novel association between the 
CCI and both OS and non-PCaSS after RP in Asian men 
with PCa. These findings have particular clinical relevance, 
as they suggest that patients with localized tumors and mul-
tiple comorbidities should be managed more conservatively.
The incidence of cardiovascular disease and metabolic 
syndrome in Asian men is different from that in Western men 
according to epidemiologic studies.29 However, Asian elders 
also have a higher risk of chronic diseases, including myo-
cardial infarction, diabetes mellitus, hypertension, stroke, 
chronic bronchitis, asthma, and peptic ulcer disease.30 In a 
Korean geriatric cohort study, 78.0% reported that they had 
a diagnosed disease, 11.0% reported being cured of previ-
ous disease, and 46.8% were diagnosed with more than two 
diseases. The mean number of morbidities per elderly Ko-
rean was 1.62±1.35.31 A westernization of diet and a reduc-
tion in physical activity may have contributed to metabolic 
imbalance, obesity, and a dramatic increase in cardiovascu-
lar disease and diabetes within the Asian community.32 Al-
though the Asian lifestyle has become westernized, the sim-
ilarities and differences between comorbidities in Asian and 
Western countries remain to be elucidated. Nonetheless, the 
relationship between comorbidity and survival in Asian 
men with PCa must be emphasized.33 CCI is clearly a valu-
able preoperative tool for evaluating and counseling Asian 
patients with PCa. An Asian-specific cormobidity index 
should be designed and made clinically available in the near 
future. Recently, a newly developed comorbidity index using 
Korean hospitalized patient data based on the ICD-10 was 
also validated.34
In summary, the CCI was independently associated with 
both OS and non-PCaSS after RP, but had no impact on 
PCaSS. Selection of RP as a curative modality for PCa should 
take a patient’s comorbidities into consideration. The CCI 
is a potentially valuable tool for preoperative evaluation 
and counseling of Asian patients with PCa. An Asian-spe-
cific cormobidity index should be designed and made clini-
cally available in the near future.
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should consider conservative management of low-risk and 
intermediate-risk tumors because of exceedingly high risk 
of death from other causes and low risk of prostate cancer 
mortality. Thus, several population-based studies on PCa 
and preoperative morbidities have been published from 
western countries. However, studies with long-term follow-
up focused on Asian populations have not been reported 
prior to our current analysis. 
Albertsen, et al.27 examined the survival probabilities for 
767 patients with localized PCa who were treated conserva-
tively (either by observation or with immediate or delayed 
androgen withdrawal therapy). The 15-, 20-, and 25-year OS 
rates in patients with a CCI of 0-1 were 26%, 15%, and 8%, 
respectively. However, the 15-, 20-, and 25-year OS rates in 
those with a CCI ≥1 were 11%, 6%, and 3%, respectively, 
clearly showing that a higher CCI correlated with a worse 
survival outcome. These long-term follow-up results with 
conservative management were similar to our results with 
RP. In addition, our study also suggested that CCI had a 
strong influence on OS and non-PCaSS, but not on PCaSS, 
in patients with organ-confined disease. These data indicate 
that patients with early-stage disease and comorbidities 
should be managed conservatively. In contrast, the signifi-
cance of CCI was different for patients with locally advanced 
or high risk PCa. Hsu, et al.28 analyzed the relationship be-
tween age, CCI, and outcome in 200 patients with cT3a PCa 
from Belgium, and concluded that the CCI did not influence 
the outcome in patients with locally advanced PCa. These re-
sults are consistent with our subgroup analysis for non-organ-
confined T3/4 disease. We could not conclude from our 
study which treatment option is optimal. Nevertheless, a 
more aggressive approach might be considered for PCa pa-
tients with advanced T3/4 disease regardless of their CCI. 
There were some limitations and intrinsic shortcomings 
due to the retrospective nature of this study. First, the sam-
ple size was relatively small compared with previous popu-
lation-based trials. Second, there is inherent selection bias 
due to the fact that patients with many comorbidities are of-
ten treated with less invasive methods, such as radiation 
therapy, hormonal therapy, or watchful waiting. Actually, the 
median PSA in Group 1 was significantly higher than Group 
2 [12.00 (7.75, 21.95) ng/mL versus 9.56 (6.12, 15.02) ng/
mL, respectively; p=0.007]. Treatment decision in our pa-
tient cohorts may be based on comorbidities, however, there 
were no statistical differences in D’Amico risk stratification 
unlike the median PSA between two groups. Third, there is 
bias derived from the differences between preoperative and 
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